Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market

MOUNTAIN VIEW, California, July 29, 2014 /PRNewswire/ — Based on its recent analysis of the personal emergency response systems (PERS) market, Frost & Sullivan recognizes MobileHelp with the 2014 North America Frost & Sullivan Award for Price Performance Value Leadership. MobileHelp’s leadership in flexibility across in-home and mobile usage directly captures expectations for tech progression in personal emergency response, and exemplifies key demands of US consumers for these solutions.

MobileHelp is at the forefront of convenience and utility in the M-PERS market and offers a simple two product option covering the range of use cases, with a uniform cellular rate plan. MobileHelp has been active in its dedication to broader mobile medical device product goals that augment its core capabilities in emergency response. Frost & Sullivan believes that both its referral branding within facility-to-home care as well as its increasing direct-to-consumer presence will allow it to expand a cost-effective product base across the medical and monitoring spectrum over time.

Primary consumer interest factors in PERS include price, reliability, contract flexibility, and customer experience of the emergency response. MobileHelp has delivered a strong value story for buyers with its simple interface and top-class emergency referral, including robust features and services provided in system pricing for its DUO series.

MobileHelp has been a pioneer in wearable devices with its wristwatch, which greatly reduces product bulk, damage through movement or falls, and issues related to daily forgetfulness of use. Secondly, the two-step transition between the Classic and DUO product suites allows customers to seamlessly upgrade from indoor-only to mixed indoor/outdoor use, with no interruption to service. MobileHelp also focuses on return guarantees, low obligatory service commitment and easy product upgrade, making its solutions very attractive for new buyers that are seeking emergency care support without product risk.

“Mobility is a key component of shifting customer expectations in personal emergency response systems,” said Frost & Sullivan Research Analyst Daniel Ruppar. Providing systems which broaden flexibility, while offering important ease of use, service support, and other high value factors supporting solution purchase decisions are key characteristics of leadership in this important Senior focused market.

Each year, Frost & Sullivan presents this award to a company that has developed a product that offers price competitiveness, ease of use, as well as service effectiveness.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development.

Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform

LONDON, July 29, 2014 /PRNewswire/ — Today, Frost & Sullivan recognizes Validic with the 2014 Global Frost & Sullivan Best Practices Award for Customer Value Leadership. The Validic mHealth interoperability solution is a cloud-based platform that connects digital health application developers, medical devices and healthcare clients – such as providers, pharmaceutical companies, prevention and wellness companies, population health management companies and consumer electronics.

Each year, Frost & Sullivan presents this award to a company that has demonstrated excellence in implementing strategies that proactively creates value for its customers with a focus on improving the return on the investment customers make in its services or products. This award recognizes Validic’s exemplary focus on enhancing the value its customers receive, including customer service, customer retention and customer base expansion.

“On analysis of the market landscape for healthcare interoperability solutions, Validic clearly stood out as generating the best value,” said Frost & Sullivan Research Analyst Shruthi Parakkal. “One of the things that sets Validic apart is the company’s focus on customers throughout the entire process,” noted Parakkal. “Furthermore, its mHealth interoperability platform is a unique technological solution with a quick deployment time of a few hours, and is 90 percent cheaper than a healthcare company trying to build a comparable mHealth solution internally. Validic is a great value to healthcare companies looking to accelerate their digital health business strategies.”

Validic constantly expands its ecosystem of mobile health apps, wearable devices and in-home medical devices by collaborating with mHealth companies of all sizes, scales and reach. Moreover, its vast repertoire of mobile integrations makes Validic’s digital health platform a great solution for enterprises, as well as emerging companies. As a result of Validic’s advanced technology, healthcare companies have convenient and quick access to healthcare patient data from a variety of devices and applications with one simple connection. 

Validic Co-founder and CEO Ryan Beckland stated, “We are truly honored to be recognized by Frost & Sullivan, who is a global industry leader in analyzing markets, industry trends and best practices.  This Best Practices Award reinforces our solid results in digital health data interoperability, is a great testament to our proven technology success, and supports how our work ultimately drives value for our customers. This recognition further validates our industry leadership position and our focus on our customers.”

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Validic

Validic is the healthcare industry’s leading technology platform for convenient, easy data access to a world of mobile health and in-home devices, wearables and patient healthcare applications. By connecting its growing base of customers — that includes providers, payers, pharmaceutical companies, wellness companies and health IT vendors — to the continuously expanding list of digital health technologies, Validic enables healthcare companies to better coordinate care across their communities, improve their patient engagement strategies, enhance their remote patient monitoring capabilities, and more efficiently manage their patient populations. Validic’s scalable, reliable and FDA Class I MDDS technology delivers actionable, standardized, HIPAA-compliant consumer health data from best in-class health devices and applications. Validic’s leading global digital health ecosystem reaches over 72 million lives and continues to grow daily. To learn more about Validic, please follow us on Twitter at @validic or visit www.validic.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:   Start the discussion

Join Us:      Join our community

Subscribe:    Newsletter on “the next big thing”

Register:     Gain access to visionary innovation

Contact:

Chris Edwards
SVP Marketing
Validic
+1-800-495-7934
chris.edwards@validic.com

Adelaide Mendes
Best Practices Group
Frost & Sullivan
Tel.: +44-(0)-207-9157869
E-mail: adelaide.mendes@frost.com

Frost & Sullivan: Integration of Services is Crucial for Patient-Centric Healthcare Systems

LONDON, July 29, 2014 /PRNewswire/ — The healthcare industry is rapidly moving from a provider-centric, individual physician expertise-based service sector to a patient-centric, consultative and analytics-driven industry. This collaborative approach will be quickened by innovations that lend momentum to the integration of healthcare systems. Integrated care services can be achieved along four lines: patient engagement, workflow management, new healthcare models, and home care.

Frost & Sullivan

Frost & Sullivan

New analysis from Frost & Sullivan, Innovations in Home Medical Devices and Integrated Care Systems, finds that the integration of healthcare systems has several connotations. Integration can either be vertical, which results in consolidation of similar services, or horizontal, which aims at expansion of organization infrastructure and patient base. Integration can also be more microscopic, involving functions, organisational policies and clinical locations.

“The holy grail of integrated care systems is achieving end-to-end integration, which would require both vertical and horizontal consolidation that results in the streamlining of treatment services, products, ancillary and support systems as well as geographical expansion,” said Technical Insights Research Analyst Bhargav Rajan.

The biggest challenge to integration, especially in emerging economies, is the highly fragmented healthcare market. Enforcing common management policies and patient services among different practices to achieve functional clinical integration will be an uphill task.

In such regions, integration can be achieved by targeting readily available avenues for growth, such as implementing technological resources to ensure care of patients at home and in the community. In turn, remote patient monitoring and telemedicine will not only serve as tools for clinical services and patient integration, but also as a means of frugal innovation.

Healthcare providers and administrators need to realise that the consolidation of practices will not necessarily lead to integration of services. Effective integration requires alignment of practices and policies as well as culture and ideologies.

“For every successful case of healthcare integration, there are several instances of failed mergers, most notably among healthcare organisations with divergent mission statements,” cautioned Rajan. “Meeting of organisation goals and resource compatibility are important criteria during mergers and horizontal expansion.”

If you are interested in more information on this study, please email Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com

Innovations in Home Medical Devices and Integrated Care Systems, a part of the Technical Insights subscription, highlights key innovations in healthcare delivery, with special focus on identifying different strategies that providers can adopt to implement integration of services. This research service also provides a holistic analysis of various component technologies in accordance with their technical capabilities, market needs and industry requirements. Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact
Anna Zanchi
Corporate Communications — Europe
P: +39-02-4851-6133
E: anna.zanchi@frost.com

http://www.frost.com

Photo – http://photos.prnasia.com/prnh/20140729/8521404286 

A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market

MOUNTAIN VIEW, California, July 29, 2014 /PRNewswire/ — Drug development for hepatitis C virus (HCV) antivirals has amplified with rising incidence rates and the intense need for curative therapy in the absence of a preventative vaccine. Change is underway as the market moves away from protease inhibitors and interferon regimens towards highly effective, easily-tolerated, interferon-free oral therapies.

Gilead’s mega blockbuster Sovaldi is the first of these novel therapies to launch into the market and is projected to hit close to $10 billion during its first year. Several strong competitors, however, are maneuvering aggressively to narrow the market gap by introducing a HCV antiviral that can outdo Gilead’s drug.

New analysis from Frost & Sullivan’s A Product and Pipeline Analysis of the Global Hepatitis C Virus (HCV) Antiviral Market expects robust demand for HCV antivirals as around 160 million people across the globe are chronically infected with HCV, and at least 350,000 die annually from HC-infected liver diseases such as liver cancer and conditions requiring transplantation. The United States alone accounts for nearly five million of the total HCV-affected population, with the majority being baby boomers entering the 65-plus age bracket.

For complimentary access to more information on this research, please visit: http://bit.ly/1lOeo6Q

“Evidently, chronic infection with HCV remains a serious public health threat,” said Frost & Sullivan Healthcare Principal Analyst Randy Budros. “Until an efficacious preventative vaccine emerges, the patient strength will remain sizable due to the likelihood of high-risk behaviors from a substantial portion of the population and the emergence of resistant viral strains.”

While Gilead’s Sovaldi holds promise in fighting the HCV, its astronomical price – $84,000 for a 12-week course of treatment – has unleashed a firestorm of criticism from government agencies, patient advocacy groups, and payers. Indeed, the prohibitive price has triggered a Congressional request for Gilead to justify its pricing, which is projected to increase Medicare Part D spending by as much as $6.5 billion in 2015 alone.

“Gilead and other future market entrants have to create a compelling pricing rationale by driving home the potential cost savings from a high-performance, all-oral regime, zeroing in on the downstream cost saving such as the reduction of liver transplants,” noted Budros. “Equally crucial is the need to make HCV antivirals more affordable and accessible to patients.”

With recent clinical data showing close to 100-percent cure rates for Sovaldi, future contenders will be hard pressed to succeed in the marketplace. Competitors must aim to satisfy the until now unmet need for a once-daily, ribavirin-free, all-oral, pan-genotypic regimen that has a short treatment duration.

A Product and Pipeline Analysis of the Global Hepatitis C Virus (HCV) Antiviral Market is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market, A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market, A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market, and Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare and LinkedIn, for the latest news and updates.

Frost & Sullivan Applauds Gamma Medica for Improving the Quality and Efficiency of Breast Cancer Diagnosis with its Unique LumaGEM MBI System

MOUNTAIN VIEW, Calif., July 29, 2014 /PRNewswire/ — Based on its recent analysis of the breast imaging systems market, Frost & Sullivan recognizes Gamma Medica with the 2014 Global Frost & Sullivan Award for Product Leadership. Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system provides breast images through the digital direct conversion of photons in gamma rays into electronic charges that form the image. It equips clinicians with MBI technology to detect tumors in women with dense breast tissue and plan treatment measures as early as possible.

Gamma Medica has demonstrated its dedication to improving the standard of care for breast cancer patients by offering the advanced cadmium zinc telluride (CZT) solid state detector technology in its LumaGEM MBI system.

“While other adjunct technologies such as ultrasound and magnetic resonance imaging are available, either their inability to locate microcalcifications or their low specificity can throw up inconclusive results,” said Frost & Sullivan Research Analyst Raghuraman Madanagopal. “On the other hand, Gamma Medica’s LumaGEM MBI system can efficiently locate lesions as small as 5 millimeters in size and help identify the tumor as benign or cancerous.”

The LumaGEM MBI system has the highest negative predictive value (NPV) among adjunct technologies used for breast cancer diagnosis, making it one of the most reliable systems for this purpose. It also has a high intrinsic spatial resolution of 1.6 millimeters and provides high-quality images that enable clinicians to locate tumors, measure them, and understand their functional and metabolic activities.

While there are shortcomings with every adjunct technology that is used for breast cancer diagnosis, the LumaGEM MBI system, with a high sensitivity of 91 percent and a high specificity of 93 percent, offers customers unprecedented precision. The LumaGEM MBI system utilizes a dual-head technology that effectively locates cancers in cases that previously were either inconclusive or determined to be negative on mammography images.

As the imaging is done on the mediolateral oblique and the cranio-caudal planes, it is easily comparable to mammography images. The scanning procedure in the LumaGEM MBI system uses minimal compression and is performed with the subject in a seated position.

“The LumaGEM MBI system has a small-sized gamma camera that is located closer to the breasts,” noted Raghuraman Madanagopal. “As a result, the amount of radiation required for obtaining images is less than one-third of the amount used in most breast-specific gamma imaging modalities. Frost & Sullivan research shows that this ability provides Gamma Medica a technological advantage over its competitors.”

“Gamma Medica is committed to making MBI a more widely used tool in the battle against breast cancer,” said Jim Calandra, president and chief executive officer of Gamma Medica. “We are pleased to have been recognized by Frost & Sullivan for our efforts and are excited to drive breast cancer diagnosis technology forward with highly advanced, patient-friendly and cost-effective tools.”

Gamma Medica has made its products commercially available throughout the United States, as well as in certain parts of Europe, and hopes to expand to other regions of the world. By utilizing innovative technologies and effective growth strategies, Gamma Medica has ensured a superior competitive position for itself in the global breast imaging systems market.

Each year, Frost & Sullivan presents this award to the company that has demonstrated innovation in product features and functionality that provides enhanced quality and higher value to customers. The award recognizes the rapid acceptance such innovation finds in the marketplace.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.